Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine in Hospitalized COVID-19 Patients
NCT04392531Phase 4Completed
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclosporine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoint: Severity Category at 12 days. Started Apr 2020; status: completed.
02
Drugs
cyclosporine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04392531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392531.